9 Meters Biopharma, Inc. (NASDAQ:NMTR) Receives $58.33 Average PT from Brokerages

Shares of 9 Meters Biopharma, Inc. (NASDAQ:NMTR – Get Rating) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $58.33.

Separately, Citigroup began coverage on 9 Meters Biopharma in a research note on Monday, February 13th. They issued a “neutral” rating on the stock.

9 Meters Biopharma Stock Performance

NMTR stock opened at $1.36 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 1.17. The business’s fifty day simple moving average is $2.04 and its two-hundred day simple moving average is $2.69. 9 Meters Biopharma has a twelve month low of $1.00 and a twelve month high of $13.20. The firm has a market cap of $17.61 million, a price-to-earnings ratio of -0.44 and a beta of 0.51.

Institutional Trading of 9 Meters Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Valeo Financial Advisors LLC boosted its position in shares of 9 Meters Biopharma by 5.8% during the third quarter. Valeo Financial Advisors LLC now owns 209,688 shares of the company’s stock worth $45,000 after buying an additional 11,540 shares during the period. HRT Financial LP raised its stake in 9 Meters Biopharma by 202.2% during the 4th quarter. HRT Financial LP now owns 42,530 shares of the company’s stock valued at $53,000 after purchasing an additional 28,455 shares during the period. Virtu Financial LLC raised its stake in 9 Meters Biopharma by 25.6% during the 3rd quarter. Virtu Financial LLC now owns 228,595 shares of the company’s stock valued at $49,000 after purchasing an additional 46,612 shares during the period. UBS Group AG increased its stake in shares of 9 Meters Biopharma by 301.3% in the second quarter. UBS Group AG now owns 114,914 shares of the company’s stock worth $30,000 after acquiring an additional 86,281 shares during the last quarter. Finally, State Street Corp increased its stake in shares of 9 Meters Biopharma by 2.5% in the first quarter. State Street Corp now owns 3,829,916 shares of the company’s stock worth $2,295,000 after acquiring an additional 91,800 shares during the last quarter.

9 Meters Biopharma Company Profile

(Get Rating)

9 Meters Biopharma, Inc is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P.